Transgenomic Company Profile (NASDAQ:TBIO)

About Transgenomic (NASDAQ:TBIO)

Transgenomic logoTransgenomic, Inc. is a biotechnology company. The Company is engaged in advancing personalized medicine for the detection and treatment of cancer, and inherited diseases through its molecular technologies and clinical and research services. The Company operates through its Laboratory Services segment. The Company is engaged in the provision of its Multiplexed ICE COLD-PCR (MX-ICP) product to the clinical market, enabling the use of blood and other bodily fluids for diagnosis, monitoring and treatment of cancer. MX-ICP amplifies the ability to detect genetic mutations by approximately 100 to 400 fold. MX-ICP is validated internally on sequencing platforms, including Sanger, Next Gen Sequencing and Digital polymerase chain reaction (PCR). Its laboratory in Omaha, Nebraska is focused on providing genetic analytical services related to oncology and pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical and biotechnology companies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Scientific & Technical Instruments
  • Sub-Industry: N/A
  • Symbol: NASDAQ:TBIO
  • CUSIP: N/A
  • Web:
  • Market Cap: $8.06 million
  • Outstanding Shares: 26,863,000
Average Prices:
  • 50 Day Moving Avg: $0.44
  • 200 Day Moving Avg: $0.45
  • 52 Week Range: $0.15 - $1.59
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.14
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $1.98 million
  • Price / Sales: 4.07
  • Book Value: ($0.78) per share
  • Price / Book: -0.38
  • EBIDTA: ($6,600,000.00)
  • Net Margins: -1,932.70%
  • Return on Assets: -267.85%
  • Current Ratio: 0.05%
  • Quick Ratio: 0.05%
  • Average Volume: 208,862 shs.
  • Beta: 0.45
  • Short Ratio: 0.31

Frequently Asked Questions for Transgenomic (NASDAQ:TBIO)

What is Transgenomic's stock symbol?

Transgenomic trades on the NASDAQ under the ticker symbol "TBIO."

How were Transgenomic's earnings last quarter?

Transgenomic Inc (NASDAQ:TBIO) posted its earnings results on Friday, August, 12th. The company reported ($0.10) earnings per share (EPS) for the quarter. The company had revenue of $0.51 million for the quarter. View Transgenomic's Earnings History.

Who are some of Transgenomic's key competitors?

How do I buy Transgenomic stock?

Shares of Transgenomic can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Transgenomic stock cost?

One share of Transgenomic stock can currently be purchased for approximately $0.30.

Analyst Ratings

Consensus Ratings for Transgenomic (NASDAQ:TBIO) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Transgenomic (NASDAQ:TBIO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/14/2015Craig HallumLower Price TargetBuy$8.00N/AView Rating Details
(Data available from 5/23/2015 forward)


Earnings History for Transgenomic (NASDAQ:TBIO)
Earnings by Quarter for Transgenomic (NASDAQ:TBIO)
Earnings History by Quarter for Transgenomic (NASDAQ:TBIO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/12/2016Q216($0.10)$0.51 millionViewListenView Earnings Details
5/23/2016Q116($0.10)$0.24 millionViewListenView Earnings Details
11/12/2015Q315($0.27)($0.18)$6.65 million$4.00 millionViewListenView Earnings Details
8/13/2015Q215($0.41)($0.30)$7.10 million$7.00 millionViewListenView Earnings Details
5/14/2015Q115($0.52)($0.36)$6.80 million$6.51 millionViewListenView Earnings Details
4/15/2015Q414($0.56)($0.77)$6.20 million$7.70 millionViewN/AView Earnings Details
10/30/2014($0.58)($0.61)$6.80 million$6.37 millionViewN/AView Earnings Details
5/7/2014($0.47)($0.60)$6.73 million$6.25 millionViewN/AView Earnings Details
3/12/2014($0.36)($0.05)$6.71 million$6.22 millionViewN/AView Earnings Details
8/6/20132Q13($0.03)($0.03)ViewN/AView Earnings Details
5/8/20131Q13($0.03)($0.04)ViewN/AView Earnings Details
3/13/20134Q12($0.03)($0.03)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Transgenomic (NASDAQ:TBIO)
Current Year EPS Consensus Estimate: $-1.45 EPS
Next Year EPS Consensus Estimate: $-2.14 EPS


Dividend History for Transgenomic (NASDAQ:TBIO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Transgenomic (NASDAQ:TBIO)
Insider Ownership Percentage: 1.90%
Institutional Ownership Percentage: 34.84%
Insider Trades by Quarter for Transgenomic (NASDAQ:TBIO)
Institutional Ownership by Quarter for Transgenomic (NASDAQ:TBIO)
Insider Trades by Quarter for Transgenomic (NASDAQ:TBIO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/22/2014Leroy C KoppMajor ShareholderSell413,050$3.70$1,528,285.00View SEC Filing  
10/2/2013Leroy C KoppMajor ShareholderBuy9,000$0.39$3,510.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Transgenomic (NASDAQ:TBIO)
Latest Headlines for Transgenomic (NASDAQ:TBIO)
DateHeadline logoPrecipio Renews its Exclusive Agreement with Yale School of Medicine for an Additional Five Years - April 20 at 9:00 PM logoFavorable Media Coverage Likely to Impact Transgenomic (TBIO) Share Price - April 18 at 3:24 PM logoTransgenomic Closes Bridge Financing - April 17 at 8:45 AM logoTransgenomic, Inc. :TBIO-US: Earnings Analysis: 2016 By the Numbers : April 14, 2017 - April 14 at 12:17 PM logoResearch Reports on Scientific & Technical Instruments Equities -- Fitbit, Transgenomic, Sensata Technologies, and ... - PR Newswire (press release) - April 7 at 12:57 PM logoTRANSGENOMIC INC Financials - February 25 at 3:30 AM logoTRANSGENOMIC INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant - February 25 at 3:30 AM logo4:22 pm Transgenomic reports that trading in its shares will begin on the OTCQB exchange under the ticker 'TBIO' effective at the open of business on February 22; update on its planned merger - February 22 at 8:42 PM logoTRANSGENOMIC INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; - February 22 at 10:12 AM logoTransgenomic Provides Update on Its Planned Merger and Reports Change in Listing Status - February 21 at 4:49 PM logoSHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Transgenomic, Inc. - TBIO - PR Newswire (press release) - February 13 at 8:38 PM logoSHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Transgenomic, Inc. - TBIO - February 13 at 8:38 PM logoTRANSGENOMIC INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits - January 20 at 7:00 AM logoTRANSGENOMIC INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Triggering Events That Accelerate or - January 17 at 11:10 PM logoTransgemonic Up Another 33% Following Yesterday's 295% Run - January 13 at 10:17 AM logoTransgenomic Inc. Announces Collaboration With LifeLabs, Shares Skyrocket 233% On News - January 12 at 11:48 PM logoTransgenomic (TBIO) Says LifeLabs Selects ICE COLD-PCR as Its Mutation Enrichment Platform - January 12 at 11:48 PM logoTransgenomic Inc. (TBIO) Has Jumped To A 9-Month High - January 12 at 11:48 PM logoTransgenomic Announces Leading Clinical Laboratory Services Provider LifeLabs Selects ICE COLD-PCR as Its Mutation Enrichment Platform - January 12 at 11:48 PM logo7:31 am Transgenomic announces Lifelabs selected its ICE COLD-PCR technology as its mutation enrichment platform for cancer testing; separately announces issuance of a new Canadian patent for ICP - January 12 at 11:48 PM logoTRANSGENOMIC INC Files SEC form 8-K, Triggering Events That Accelerate or Increase a Direct Financial Obligation or a - January 7 at 5:53 AM


Transgenomic (TBIO) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by Staff